How to Address One of the Costliest Health Challenges in the U.S.: Diabetes

Diabetes is one of the most costly and prevalent disease states for most health insurers. A comprehensive plan to manage it is crucial to addressing health and affordability challenges that could affect one in three Americans.
Women Resting

Diabetes is continuing to grow in our country and across the world, so we relentlessly continue to examine this serious condition and how we can provide better health outcomes for patients by interfering before they’re diagnosed, and make caring for those with diabetes more affordable for clients. 

No more sugar coating

One out of three people in the U.S. has the potential to need treatment for diabetes. It is the 7th leading cause of death in the U.S. Not only that, with a 20% trend over the next three years, health insurers continue to grapple with how to control costs. In all, see how diabetes totals $210,000,000 in potential avoidable costs each year.

The Sweet Relief

Non-adherence is one of the costliest drivers of diabetes costs. Specifically, 16%-19% is the rate of cost-related medication non-adherence (CRN) among patients with diabetes, defined as taking medication less than as prescribed because of cost. This means that the average plan pays $5,427 in care expenses for a nonadherent member with diabetes, but it doesn’t need to be that way. See innovative solutions and personalized approaches to care that can control costs and decrease non-adherence.

The Sweet Taste of Victory

As we’ve seen, diabetes is a challenging disease to control, but together, we can do more to optimize patients’ experience and curb avoidable costs. See how a unique, personalized approach can make a difference.

Diabetes can be a life-long battle for some patients and an ongoing challenge for health insurers. As health care partners, it’s all of our jobs to do more to address this important condition in pursuit of healthier and more affordable outcomes for all.


Stay Informed
Subscribe to our newsletter for regular updates and the latest thinking from our experts.